Advertisement

Design, synthesis, and in silico studies of novel eugenyloxy propanol azole derivatives having potent antinociceptive activity and evaluation of their β-adrenoceptor blocking property

  • Somayeh Behrouz
  • Mohammad Navid Soltani Rad
  • Bahareh Taghavi Shahraki
  • Mohammad Fathalipour
  • Marzieh Behrouz
  • Hossein Mirkhani
Original Article

Abstract

The design, synthesis, antinociceptive and β-adrenoceptor blocking activities of several eugenyloxy propanol azole derivatives have been described. In this synthesis, the reaction of eugenol with epichlorohydrin provided adducts 3 and 4 which were N-alkylated by diverse azoles to obtain the eugenyloxy propanol azole analogues in good yields. Adducts 3 and 4 were also reacted with azide ion to obtain the corresponding azide 6. The ‘Click’ Huisgen cycloaddition reaction of 6 with diverse alkynes afforded the title compounds in good yields. The synthesized eugenyloxy propanol azole derivatives were in vivo studied for the acute antinociception on male Spargue Dawley rats using tail-flick test. Compounds 5f, 5g, 7b and 11a exhibited potent analgesic properties in comparison with eugenol as a standard drug. In addition, all compounds were ex vivo tested for β-adrenoceptor blocking properties on isolated left atrium of male rats which exhibited partial antagonist or agonist behaviour compared to the standard drugs. The molecular docking study on the binding site of transient receptor potential vanilloid subtype 1 (TRPV1) has indicated that like capsaicin, eugenyloxy propanol azole analogues exhibited the strong affinity to bind at site of TPRV1 in a “tail-up, head-down” conformation and the presence of triazolyl moieties has played undeniable role in durable binding of these ligands to TRPV1. The in silico pharmacokinetic profile, drug likeness and toxicity predictions carried out for all compounds determined that 5g can be considered as potential antinociceptive drug candidate for future research.

Keywords

Eugenol Eugenyloxy propanol azole Antinociceptive β-Adrenoceptor Antagonist Agonist 

Notes

Acknowledgements

The authors wish to thank Shiraz University of Technology research council for partial support of this work. The authors are thankful from the High Performance Computing research laboratory of Institute for Research in Fundamental Sciences (IPM).

Compliance with ethical standards

Conflicts of interest

The authors declare that they have no conflict of interest.

Supplementary material

11030_2018_9867_MOESM1_ESM.pdf (1.6 mb)
Supplementary material 1 (PDF 1647 kb)

References

  1. 1.
    Nahin RL (2015) Estimates of pain prevalence and severity in adults: United States, 2012. J Pain 16:769–780.  https://doi.org/10.1016/j.jpain.2015.05.002 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Pain. https://en.wikipedia.org/wiki/Pain. Accessed 6 Jan 2018
  3. 3.
    Kingston DGI (2011) Modern natural products drug discovery and its relevance to biodiversity conservation. J Nat Prod 74:496–511.  https://doi.org/10.1021/np100550t CrossRefPubMedGoogle Scholar
  4. 4.
    Bhuiyan MNI, Begum J, Chandra Nandi N, Akter F (2010) Constituents of the essential oil from leaves and buds of clove (Syzigium caryophyllatum (L.) alston). Afr J Plant Sci 4:451–454Google Scholar
  5. 5.
    Schmalz G, Arenholt-Bindslev D (2009) Biocompatibility of dental materials. Springer, HeidelbergGoogle Scholar
  6. 6.
    Yogalakshmi B, Viswanathan P, Anuradha CV (2010) Investigation of antioxidant, anti-inflammatory and DNA-protective properties of eugenol in thioacetamide-induced liver injury in rats. Toxicology 268:204–212.  https://doi.org/10.1016/j.tox.2009.12.018 CrossRefPubMedGoogle Scholar
  7. 7.
    Rojo L, Vazquez B, Roman JS, Deb S (2008) Eugenol functionalized poly(acrylic acid) derivatives in the formation of glass-ionomer cements. Dent Mater 24:1709–1716.  https://doi.org/10.1016/j.dental.2008.04.004 CrossRefPubMedGoogle Scholar
  8. 8.
    Schmidt E, Jirovetz L, Wlcek K, Buchbauer G, Gochev V, Girova T, Stoyanova A, Geissler M (2007) Antifungal activity of eugenol and various eugenol-containing essential oils against 38 clinical isolates of Candida albicans. J Essent Oil Bear Plants 10:421–429.  https://doi.org/10.1080/0972060x.2007.10643575 CrossRefGoogle Scholar
  9. 9.
    Prakash P, Gupta N (2005) Therapeutic uses of Ocimum sanctum linn (tulsi) with a note on eugenol and its pharmacological actions: a short review. Indian J Physiol Pharmacol 49:125–131PubMedGoogle Scholar
  10. 10.
    Awasthi PK, Dixit SC, Dixit N, Sinha AK (2008) Eugenol derivatives as future potential drugs. J Pharm Res 1:215–220Google Scholar
  11. 11.
    Burt SA, Reinders RD (2003) Antibacterial activity of selected plant essential oils against Escherichia coli O157:H7. Lett Appl Microbiol 36:162–167.  https://doi.org/10.1046/j.1472-765x.2003.01285.x CrossRefPubMedGoogle Scholar
  12. 12.
    Kim SI, Yi JH, Tak JH, Ahn YJ (2004) Acaricidal activity of plant essential oils against Dermanyssus gallinae (Acari: Dermanyssidae). Vet Parasitol 120:297–304.  https://doi.org/10.1016/j.vetpar.2003.12.016 CrossRefPubMedGoogle Scholar
  13. 13.
    Li Y, Xu C, Zhang Q, Liu JY, Tan RX (2005) In vitro anti-helicobacter pylori action of 30 chinese herbal medicines used to treat ulcer diseases. J Ethnopharmacol 98:329–333.  https://doi.org/10.1016/j.jep.2005.01.020 CrossRefPubMedGoogle Scholar
  14. 14.
    Pisano M, Pagnan G, Loi M, Mura ME, Tilocca MG, Palmieri G, Fabbri D, Dettori MA, Delogu G, Ponzoni M, Rozzo C (2007) Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells. Mol Cancer 6(8):1–12.  https://doi.org/10.1186/1476-4598-6-8 Google Scholar
  15. 15.
    Zhao X, Chen D, Gao P, Ding P, Li K (2005) Synthesis of ibuprofen eugenol ester and its microemulsion formulation for parenteral delivery. Chem Pharm Bull 53:1246–1250.  https://doi.org/10.1248/cpb.53.1246 CrossRefPubMedGoogle Scholar
  16. 16.
    Kaufman TS (2015) The multiple faces of eugenol. A versatile starting material and building block for organic and bio-organic synthesis and a convenient precursor toward bio-based fine chemicals. J Braz Chem Soc 26:1055–1085.  https://doi.org/10.5935/0103-5053.20150086 Google Scholar
  17. 17.
    Bendre RS, Rajput JD, Bagul SD, Karandikar PS (2016) Outlooks on medicinal properties of eugenol and its synthetic derivatives. Nat Prod Chem Res 4(3):100212–1000217.  https://doi.org/10.4172/2329-6836.1000212 CrossRefGoogle Scholar
  18. 18.
    Fonseca-Berzal C, Ruiz FAR, Escario JA, Kouznetsov VV, Gómez-Barrio A (2014) In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti- Trypanosoma cruzi agents. Bioorg Med Chem Lett 24:1209–1213.  https://doi.org/10.1016/j.bmcl.2013.12.071 CrossRefPubMedGoogle Scholar
  19. 19.
    Arango V, Domínguez JJ, Cardona W, Robledo SM, Muñoz SL, Figadere B, Sáez J (2012) Synthesis and leishmanicidal activity of quinoline–triclosan and quinoline–eugenol hybrids. Med Chem Res 21:3445–3454.  https://doi.org/10.1007/s00044-011-9886-8 CrossRefGoogle Scholar
  20. 20.
    Chen H, Li G, Zhan P, Guo X, Ding Q, Wang S, Liu X (2013) Design, synthesis and biological evaluation of novel ligustrazinylated derivatives as potent cardiovascular agents. Med Chem Commun 4:827–832.  https://doi.org/10.1039/c3md20352b CrossRefGoogle Scholar
  21. 21.
    Hernández D, Bernal P, Cruz A, Garciafigueroa Y, Garduño L, Salazar M, Díaz F, Chamorro G, Tamariz J (2004) Potent hypolipidemic activity of mimetic amides of fibrates based on the 2-methoxy-4-(2-propenyl)phenoxyacetic scaffold. Drug Dev Res 61:19–36.  https://doi.org/10.1002/ddr.10333 CrossRefGoogle Scholar
  22. 22.
    Huang YC, Wu BN, Yeh JL, Chen SJ, Liang JC, Lo YC, Chen IJ (2001) A new aspect of view in synthesizing new type beta-adrenoceptor blockers with ancillary antioxidant activities. Bioorg Med Chem 9:1739–1746.  https://doi.org/10.1016/S0968-0896(01)00067-0 CrossRefPubMedGoogle Scholar
  23. 23.
    Bhat KI, Hussain MMM (2009) Synthesis, characterization and antimicrobial studies of some substituted pyrazolines from aryloxy acetyl hydrazine. Asian J Chem 21:3371–3375Google Scholar
  24. 24.
    Dallmeier K, Carlini EA (1981) Anesthetic, hypothermic, myorelaxant and anticonvulsant effects of synthetic eugenol derivatives and natural analogues. Pharmacology 22:113–127.  https://doi.org/10.1159/000137479 CrossRefPubMedGoogle Scholar
  25. 25.
    Seixas Xavier FJ, da Franca Rodrigues KA, de Oliveira RG, Lima Junior CG, da Câmara RJ, Lima Keesen TS, de Oliveira MR, Lins Silva FP, de Almeida Vasconcellos MLA (2016) Synthesis and in vitro anti Leishmania amazonensis biological screening of Morita-Baylis-Hillman adducts prepared from eugenol, thymol and carvacrol. Molecules 21:1483.  https://doi.org/10.3390/molecules21111483 CrossRefGoogle Scholar
  26. 26.
    Budavari S, O’Neil MJ, Smith A, Heckelman PE (2001) The merck index: an encyclopedia of chemicals, drugs, and biologicals, 13th edn. Merck & Co., Inc, Whitehouse StationGoogle Scholar
  27. 27.
    d’Avila Farias M, Oliveira PS, Dutra FSP, Fernandes TJ, de Pereira CMP, de Oliveira SQ, Stefanello FM, Lencina CL, Barschak AG (2013) Eugenol derivatives as potential anti-oxidants: is phenolic hydroxyl necessary to obtain an effect? J Pharm Pharmacol 66:733–746.  https://doi.org/10.1111/jphp.12197 CrossRefPubMedGoogle Scholar
  28. 28.
    Abdul Rahim NHC, Asari A, Ismail N, Osman H (2017) Synthesis and antibacterial study of eugenol derivatives. Asian J Chem 29:22–26.  https://doi.org/10.14233/ajchem.2017.20100 CrossRefGoogle Scholar
  29. 29.
    Chen SJ, Wang MH, Chen IJ (1996) Antiplatelet and calcium inhibitory properties of eugenol and sodium eugenol acetate. Gen Pharmacol 27:629–633.  https://doi.org/10.1016/0306-3623(95)02089-6 CrossRefPubMedGoogle Scholar
  30. 30.
    Zhang P, Zhang E, Xiao M, Chen C, Xu W (2013) Enhanced chemical and biological activities of a newly biosynthesized eugenol glycoconjugate, eugenol α-d-glucopyranoside. Appl Microbiol Biotechnol 97:1043–1050.  https://doi.org/10.1007/s00253-012-4351-2 CrossRefPubMedGoogle Scholar
  31. 31.
    Chen SJ, Huang YC, Wu BN, Chen IJ (1997) Eugenolol: AN eugenol-derived β-adrenoceptor blocker with partial β2-agonist and calcium mobilization inhibition associated vasorelaxant activities. Drug Dev Res 40:239–250.  https://doi.org/10.1002/(sici)1098-2299(199703)40:3%3c239:aid-ddr4%3e3.0.co;2-l CrossRefGoogle Scholar
  32. 32.
    A global brief on hypertension. http://apps.who.int/iris/bitstream/10665/79059/1/WHO_DCO_WHD_2013.2_eng.pdf. Accessed 6 Jan 2017
  33. 33.
    Staessen JA, Gasowski J, Wang JG, Thijs L, Hond ED, Boissel JP, Coope J, Ekbom T, Gueyffier F, Liu L, Kerlikowske K, Pocock S, Fagard RH (2000) Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 355:865–872.  https://doi.org/10.1016/s0140-6736(99)07330-4 CrossRefPubMedGoogle Scholar
  34. 34.
    Wilson CO, Gisvold O, Block JH (2004) Wilson and Gisvold’s textbook of organic medicinal and pharmaceutical chemistry, 11th edn. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
  35. 35.
    Brunton LL, Lazo JS, Parker KL (2006) Goodman and Gilman’s the pharmacological basis of therapeutics, 11th edn. McGraw-Hill, New YorkGoogle Scholar
  36. 36.
    Patrick GL (2001) An introduction to medicinal chemistry, 2nd edn. Oxford University Press, New YorkGoogle Scholar
  37. 37.
    Gorre F, Vandekerckhove H (2010) Beta-blockers: focus on mechanism of action. Which beta-blocker, when and why? Acta Cardiol 65:565–570.  https://doi.org/10.1080/ac.65.5.2056244 CrossRefPubMedGoogle Scholar
  38. 38.
    Kleeman A, Engel J, Kutscher B, Reichert D (1999) Pharmaceutical substances, 3rd edn. Thieme, StuttgartGoogle Scholar
  39. 39.
    El Hadri A, Nicolle E, Leclerc G, Pietri-Rouxel F, Strosberg AD, Archimbault P (2003) New series of N-substituted phenyl ketone oxime ethers: synthesis and bovine β3-adrenergic agonistic activities. Pharmazie 58:13–17PubMedGoogle Scholar
  40. 40.
    Soltani Rad MN, Behrouz S, Dianat M (2008) Aqueous-mediated ring opening of epoxides with oximes: a rapid entry into β-hydroxy oxime O-ethers as potential β-adrenergic blocking agents. Synthesis 13:2055–2064.  https://doi.org/10.1055/s-2008-1067122 CrossRefGoogle Scholar
  41. 41.
    Soltani Rad MN, Behrouz S, Karimitabar F, Khalafi-Nezhad A (2012) ‘Click synthesis’ of some novel O-substituted oximes containing 1,2,3-triazole-1,4-diyl residues as new analogs of β-adrenoceptor antagonists. Helv Chim Acta 95:491–501.  https://doi.org/10.1002/hlca.201100324 CrossRefGoogle Scholar
  42. 42.
    Soltani Rad MN, Behrouz S, Doroodmand MM, Movahediyan A (2012) Copper-doped silica cuprous sulfate (CDSCS) as a highly efficient and new heterogeneous nano catalyst for [3+2] Huisgen cycloaddition. Tetrahedron 68:7812–7821.  https://doi.org/10.1016/j.tet.2012.07.032 CrossRefGoogle Scholar
  43. 43.
    Soltani Rad MN, Behrouz S, Movahedian A, Doroodmand MM, Ghasemi Y, Rasoul-Amini S, Ahmadi Gandomani A-R, Rezaie R (2013) Doped nano-sized copper(I) oxide (Cu2O) on melamine-formaldehyde resin: a highly efficient heterogeneous nano catalyst for ‘Click’ synthesis of some novel 1H-1,2,3-triazole derivatives having antibacterial activity. Helv Chim Acta 96:688–701.  https://doi.org/10.1002/hlca.201200224 CrossRefGoogle Scholar
  44. 44.
    Soltani Rad MN, Behrouz S, Zarenezhad E, Moslemin MH, Zarenezhad A, Mardkhoshnood M, Behrouz M, Rostami S (2014) Synthesis of fluorene and/or benzophenone O-oxime ethers containing amino acid residues and study of their cardiovascular and antibacterial effects. Med Chem Res 23:3810–3822.  https://doi.org/10.1007/s00044-014-0967-3 CrossRefGoogle Scholar
  45. 45.
    Zhang Q, Ren H, Baker GL (2014) An economical and safe procedure to synthesize 2-hydroxy-4-pentynoic acid: a precursor towards ‘clickable’ biodegradable polylactide. Beilstein J Org Chem 10:1365–1371.  https://doi.org/10.3762/bjoc.10.139 CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Asl MK, Nazariborun A, Hosseini M (2013) Analgesic effect of the aqueous and ethanolic extracts of clove. Avicenna J Phytomed 3:186–192Google Scholar
  47. 47.
    Park CK, Kim K, Jung SJ, Kim MJ, Ahn DK, Hong SD, Kim JS, Oh SB (2009) Molecular mechanism for local anesthetic action of eugenol in the rat trigeminal system. Pain 144:84–94.  https://doi.org/10.1016/j.pain.2009.03.016 CrossRefPubMedGoogle Scholar
  48. 48.
    Daniel AN, Sartoretto SM, Schmidt G, Caparroz-Assef SM, Bersani-Amado CA, Cuman RKN (2009) Anti-inflammatory and antinociceptive activities A of eugenol essential oil in experimental animal tests. Rev Bras Farmacogn 19:212–217.  https://doi.org/10.1590/s0102-695x2009000200006 CrossRefGoogle Scholar
  49. 49.
    Tadiwos Y, Nedi T, Engidawork E (2017) Analgesic and anti-inflammatory activities of 80% methanol root extract of Jasminum abyssinicum Hochst. ex. Dc. (Oleaceae) in mice. J Ethnopharmacol 202:281–289.  https://doi.org/10.1016/j.jep.2017.02.036 CrossRefPubMedGoogle Scholar
  50. 50.
    Schunck RVA, Macedo IC, Laste G, de Souza A, Valle MTC, Salomon JLO, Nunes EA, Campos ACW, Gnoatto SCB, Bergold AM, Konrath EL, Dallegrave E, Arbo MD, Torres ILS, Leal MB (2017) Standardized Passiflora incarnata L. extract reverts the analgesia induced by alcohol withdrawal in rats. Phytother Res 31:1199–1208.  https://doi.org/10.1002/ptr.5839 CrossRefPubMedGoogle Scholar
  51. 51.
    Huang YC, Wu BN, Lin YT, Chen SJ, Chiu CC, Cheng CJ, Chen IJ (1999) Eugenodilol: a third-generation beta-adrenoceptor blocker, derived from eugenol, with alpha-adrenoceptor blocking and beta2-adrenoceptor agonist-associated vasorelaxant activities. J Cardiovasc Pharmacol 34:10–20.  https://doi.org/10.1097/00005344-199907000-00003 CrossRefPubMedGoogle Scholar
  52. 52.
    Jara-Oseguera A, Simon SA, Rosenbaum T (2008) TRPV1: on the road to pain relief. Curr Mol Pharmacol 1:255–269.  https://doi.org/10.2174/1874-470210801030255 CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389:816–824.  https://doi.org/10.1038/39807 CrossRefPubMedGoogle Scholar
  54. 54.
    Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, Raumann BE, Basbaum AI, Julius D (1998) The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 21:531–543.  https://doi.org/10.1016/s0896-6273(00)80564-4 CrossRefPubMedGoogle Scholar
  55. 55.
    Julius D (2013) TRP channels and pain. Annu Rev Cell Dev Biol 29:355–384.  https://doi.org/10.1146/annurev-cellbio-101011-155833 CrossRefPubMedGoogle Scholar
  56. 56.
    Szallasi A, Blumberg PM (1990) Specific binding of resiniferatoxin, an ultrapotent capsaicin analog, by dorsal root anglion membranes. Brain Res 524:106–111.  https://doi.org/10.1016/0006-8993(90)90498-z CrossRefPubMedGoogle Scholar
  57. 57.
    Basbaum AI, Bautista DM, Scherrer G, Julius D (2009) Cellular and molecular mechanisms of pain. Cell 139:267–284.  https://doi.org/10.1016/j.cell.2009.09.028 CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Liao M, Cao E, Julius D, Cheng Y (2013) TRPV1 structures in distinct conformations reveal activation mechanisms. Nature 504:113–118.  https://doi.org/10.1038/nature12823 CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Darré L, Domene C (2015) Binding of capsaicin to the TRPV1 ion channel. Mol Pharm 12:4454–4465.  https://doi.org/10.1021/acs.molpharmaceut.5b00641 CrossRefPubMedGoogle Scholar
  60. 60.
    Thomsen R, Christensen MH (2006) MolDock: a new technique for high-accuracy molecular docking. J Med Chem 49:3315–3321.  https://doi.org/10.1021/jm051197e CrossRefPubMedGoogle Scholar
  61. 61.
    Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR et al (2009) Gaussian 09, Revision A.01 Gaussian, Inc., Wallingford CTGoogle Scholar
  62. 62.
    Bienstock RJ (2011) Library design, search methods, and applications of fragment-based drug design. American Chemical Society, WashingtonCrossRefGoogle Scholar
  63. 63.
    Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3–26.  https://doi.org/10.1016/s0169-409x(00)00129-0 CrossRefPubMedGoogle Scholar
  64. 64.
    Lipinski CA (2004) Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today 1:337–341.  https://doi.org/10.1016/j.ddtec.2004.11.007 CrossRefGoogle Scholar
  65. 65.
    Download DataWarrior V4.7.2. http://www.openmolecules.org/datawarrior/download.html. Accessed 2 Jan 2018

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Somayeh Behrouz
    • 1
  • Mohammad Navid Soltani Rad
    • 1
  • Bahareh Taghavi Shahraki
    • 1
  • Mohammad Fathalipour
    • 2
  • Marzieh Behrouz
    • 1
  • Hossein Mirkhani
    • 2
  1. 1.Medicinal Chemistry Research Laboratory, Department of ChemistryShiraz University of TechnologyShirazIran
  2. 2.Faculty of PharmacyShiraz University of Medical Science, Medicinal and Natural Products Chemistry Research CenterShirazIran

Personalised recommendations